An innovative non-contact and harmless screening modality set to change the course of breast cancer detection and patient monitoring
Female breast cancer is the most diagnosed cancer worldwide. In 2020, the International Agency for Research on Cancer estimated more than 2.26 million new cases of breast cancer. Early detection is crucial to survival; recovery rates approach 90% when detected in early stages. National population-based cancer screening programmes in Europe currently implement 3 standard imaging modalities: mammography, ultrasound and MRI. The downsides of these screening methods include ionising radiation, high costs and high false positive rates in screening results.
ThermoBreast’s multidisciplinary consortium of 16 partners from 10 countries aims to contribute to EU’s Mission on Cancer and Beating Cancer Plan by drastically improving the prevention, diagnosis and monitoring of breast cancer while reducing the burden on women and female patients and their families, health care professionals and others who are directly or indirectly affected by breast cancer.
ThermoBreast proposes a new solution for accurate, harmless and non-contact screening, equally applicable for all age groups and breast densities and capable of detecting pre-cancerous states. This risk-free screening technology, recently patented by the project coordinator ThermoMind LTD, can detect vascular anomalies and asymmetry, caused by cancerous growth. It combines innovative screening through multiple sensitive infrared sensors with advanced AI analysis of temporal dynamic thermal patterns. Through its patient-centred integrated diagnostics approach, this project converges intelligent computer vision, blood vessel extraction and tissue analysis with advanced information technology to deliver a medical class 1 device that will be validated in an international multicentre clinical study. To enhance stakeholder participation, ThermoBreast involves end users, SSH experts and a patient organisation in the co-creation of the new screening solution and assesses its health and socio-economic benefits as well as its cost effectiveness.
ThermoBreast achieved the highest possible score (15 out of 15) and was invited for grant preparation by the EC in early August. As the grant preparation process is ongoing, the successful project start is subject to the signing of the EC Grant Agreement by early November.Coordinator:
ThermoMind LTD, IL
- Cyber One GmbH, DE
- Technion, Israel Institute of Technology, IL
- Technische Universität München, DE
- Academisch Ziekenhuis Groningen, NL
- Vrije Universiteit Brussel, BE
- Cancer Patients Europe, BE
- Hadassah Medical Organization, IL
- Institut Gustave Roussy, FR
- Lietuvos Sveikatos Mokslu Universiteto Ligonine Kauno Klinikos, LT
- Sheba Medical Center, IL
- University College Cork, IE
- Universitatsklinikum Heidelberg, DE
- Univerzitetni klinicni center Maribor, SI
- accelopment Schweiz AG, CH